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 Background Ras-related nuclear protein (Ran) is required for cancer cell survival in vitro and human cancer progression, but 
the molecular mechanisms are largely unknown.
 Methods We investigated the effect of the v-myc myelocytomatosis viral oncogene homolog (Myc) on Ran expression by 
Western blot, chromatin immunoprecipitation, and luciferase reporter assays and the effects of Myc and Ran 
expression in cancer cells by soft-agar, cell adhesion, and invasion assays. The correlation between Myc and Ran 
and the association with patient survival were investigated in 14 independent patient cohorts (n = 2430) and ana-
lyzed with Spearman’s rank correlation and Kaplan–Meier plots coupled with Wilcoxon–Gehan tests, respectively. 
All statistical tests were two-sided.
 Results Myc binds to the upstream sequence of Ran and transactivates Ran promoter activity. Overexpression of Myc 
upregulates Ran expression, whereas knockdown of Myc downregulates Ran expression. Myc or Ran overexpres-
sion in breast cancer cells is associated with cancer progression and metastasis. Knockdown of Ran reverses the 
effect induced by Myc overexpression in breast cancer cells. In clinical data, a positive association between Myc 
and Ran expression was revealed in 288 breast cancer and 102 lung cancer specimens. Moreover, Ran expres-
sion levels differentiate better or poorer survival in Myc overexpressing breast (χ2 = 24.1; relative risk [RR] = 9.1, 
95% confidence interval [CI] = 3.3 to 24.7, P < .001) and lung (χ2 = 6.04; RR = 2.8, 95% CI = 1.2 to 6.3; P = .01) cancer 
cohorts.
 Conclusions Our results suggest that Ran is required for and is a potential therapeutic target of Myc-driven cancer progression 
in both breast and lung cancers.
  J Natl Cancer Inst 
Ras-related nuclear protein (Ran) GTPase is a small GTPase 
belonging to the Ras superfamily. Unlike other members, Ran lacks 
a cysteine residue at its C-terminus and hence does not undergo 
prenylation. Instead, it has an acidic C-terminal sequence—
DEDDDL—that is essential for its cellular functions, includ-
ing nucleocytoplasmic transportation, mitosis, and centrosome 
reduplication (1–3). The importance of Ran in tumorigenesis and 
as a cancer therapeutic target has been described in recent stud-
ies (4–6). Ran is overexpressed in cancer cell lines and tumor tis-
sues at both the mRNA and protein levels compared with normal 
counterparts (4). Ran expression is required for mitosis of cancer 
cells but not normal cells (5,6). Cancer cells with K-Ras activat-
ing mutations are more dependent on Ran expression than their 
K-Ras wild-type counterparts (7,8). Ran expression is required for 
the survival of cancer cells with hyperactivation of the PI3K/Akt/
mTORC1 and Ras/MEK/ERK pathways (8). Ran is also a poor 
prognostic marker in breast, lung, and ovarian cancers and renal 
cell carcinoma (8–10). In addition, we and others have shown that 
Ran overexpression may play a role in the metastatic development 
of breast and lung cancers, highlighting a novel role of Ran in can-
cer progression (11,12).
The v-myc myelocytomatosis viral oncogene homolog (Myc) is 
an important oncogene that drives tumorigenesis by modulating 
various biological responses through transcriptional activation of 
its target genes (13). Recently, Myc expression has been shown to 
be associated with a “poor prognosis” signature, which is, in turn, 
associated with the development of distant metastases (14,15). 
Among other genes, Ran has been shown to be upregulated 
by Myc in a rat cDNA microarray study (16). Indeed, in silico 
prediction of transcription factor binding sites using Ran promoter 
sequence also revealed two potential Myc binding E-box elements 
(Supplementary Figure  1, available online). Given the important 
roles of Ran in cancer development and progression, it is important 
to study the transcriptional regulation of Ran expression, which 
may in turn explain its increased expression in cancer patients with 
poorer prognosis (8).
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Methods and Materials
Cell Culture Conditions
Immortalized human breast epithelial cell line MCF10A and its 
Ras-transformed derivative MCF10AT (Karmanos Cancer Center, 
Detroit, MI; not authentically tested; cells were within 20 passages 
upon receipt from the donor) were maintained in Dulbecco’s modi-
fied Eagle medium/F-12 containing 5% horse serum, 10 μg/mL 
insulin, 20 ng/mL epidermal growth factor, 100 ng/mL cholera-
toxin, and 0.5  μg/mL hydrocortisone. Viral Packaging cell lines 
293T (American Type Culture Collection [ATCC] Manassas, 
VA) and Phoenix Ampho (gift from Nolan Laboratory, Stanford 
University, CA; not authentically tested; cells were within 20 pas-
sages upon receipt from the donor) were maintained in Dulbecco’s 
modified Eagle medium containing 10% fetal bovine serum. Breast 
cancer cell lines MCF-7 (ATCC) and MDA MB 231 (ATCC) and 
lung cancer cell line A549 (ATCC) were cultured in Dulbecco’s 
modified Eagle medium containing 10% fetal bovine serum. Breast 
cancer cell line T47D (ATCC) was maintained in Roswell Park 
Memorial Institute 1640 medium containing 10% fetal bovine 
serum. MCF10AT and Phoenix Ampho cells were phenotypically 
verified. The cell lines from ATCC were authenticated by short 
tandem repeat profiling by ATCC and expanded upon receipt. Cell 
lines used in were within 30 passage upon receipt, and cells were 
split in a 3- to 5-day interval, and tested for mycoplasia contamina-
tion once a month.
5’ Rapid Amplification of cDNA Ends (RACE) Assay
A 5’ RACE assay was performed according to the manufac-
turer’s instructions (Roche, Burgess Hill, UK) using the fol-
lowing three Ran promoter specific primers (RPSP): RPSP-1: 
5’-CAGGTCATCATCCTCATCCGG-3’; RPSP-2: 5’-TGTT- 
GCCACACAACACAATG-3’; RPSP-3: 5’-CAAGGTGGCTAC- 
ATACTT-3’.
Plasmid
Ran cDNA was amplified by Phusion Hot Start High-Fidelity 
DNA Polymerase (New England Biolabs, Hitchin, UK) using total 
cDNA from MDA MB 231 cells and the forward primers RancdsF 
(5’-ATT GCG CTT CCG CCA TCT TT-3’) and RancdsR 
(5’-GCT CCA GCT TCA TTC TCA CA-3’), and cloned into 
pBabe-puro retroviral over-expression vector. pBabe-Myc-zeo 
was a gift from R. Weinberg, and pRetrosuper shMyc was a gift 
from M. Eilers. pLKO.1-shRan1 (CCGGGCACAGTATGAGC- 
AC G AC T TAC T C G AG TA AG T C G T G C T C ATAC T- 
GTGCTTTTTTG) and pLKO.1-shRan5 (CCGGCAGTTC- 
A A AC T T G TAT T G G T T C T C G AG A AC C A ATAC A A - 
GTTTGAACTGTTTTTTG) were obtained from Sigma-
Aldrich (Dorset, UK). The Ran promoter (718 base pairs upstream 
of the transcription start site) was amplified using Phusion Hot 
Start High-Fidelity DNA Polymerase and cloned into pGL3 basic 
reporter construct (Promega, Southampton, UK).
Generation of Cell Lines
Transfection was performed using GeneJuice (Promega) accord-
ing to the manufacturer’s instruction. MCF10A pBabe-vector and 
MCF10A pBabe-Myc cells were generated by stable transfec-
tion by selecting cells in the appropriate amounts of antibiotics. 
MCF10A-vector and MCF10A-Ran cells were generated by ret-
roviral infection of pBabe-vector and pBabe-Ran plasmids, respec-
tively. MDA MB 231-shScr (Scramble) and MDA MB 231-shcMyc 
cells were generated by retroviral infection of pRetrosuper-shScr 
and pRetrosuper-shcMyc, respectively. MDA MB 231-shScr and 
MDA MB 231-shRan cells were generated by lentiviral infection 
of pLKO.1-shScr and pLKO.1-shRan5, respectively, as previously 
described (8). The stable cells were used only when they were 
within 5 passages after establishment.
Western Blot
Western blotting was performed as previously described (8). 
Antibodies for Ran (from rabbits; Millipore, Watford, UK) were 
used at 1:1000 dilution; antibodies for Myc (from mice; Santa Cruz 
Biotechnology, Santa Cruz, CA) were used at a dilution of 1:1000; 
and those for Actin (from mice; Sigma-Aldrich) were used at a dilu-
tion of 1:5000. The fold change in protein level was determined by 
densitometry.
Measurement of Ran Activity
Ran activity was measured using the Ran activation assay kit 
according to the manufacturer’s instructions (Cell Biolabs, 
San Diego, CA). Briefly, GTP-bound Ran was pulled down 
by using RanBP1 PBD Agarose bead slurry, and the pulled-
down complex was then dissociated by boiling in 2× reduc-
ing sodium dodecyl sulfate polyacrylamide gel electrophoresis 
sample buffer. The pull-down supernatant was then analyzed 
by Western blotting.
Soft Agar, Cell Adhesion, and Invasion Assays
These biological assays were performed as previously described 
(17). For soft agar assay, 5000 suspension cells in normal medium 
containing 0.35% (w/v) low-melting-point agarose were over-
laid onto a solidified normal medium containing 0.7% (w/v) low-
melting-point agarose. Cells were incubated at 37oC with 5% 
(v/v) carbon dioxide for 2 to 3 weeks. Colonies were visualized by 
staining with crystal violet and counted. For cell adhesion assay, 
40 000 cells in suspension were seeded per well in a 96-well plate 
and were allowed to settle for 30 and 60 minutes. Suspended 
cells were removed by washing four times with phosphate-buff-
ered saline, and adhered cells were then fixed with 70% (v/v) 
ethanol and stained with crystal violet. The excess crystal vio-
let was washed away with deionized water, and the retained dye 
was extracted with 70% ethanol. The absorbance at 595 nm was 
measured in a microplate reader. For the invasion assay, 50 000 
cells in serum- and phenol red–free medium were seeded into 
the upper layer of the transwell insert containing Matrigel (BD 
Biosciences, San Jose, CA). Invasion through Matrigel was 
allowed to take place for 24 hours with serum as the chemoat-
tractant in the lower layer. Cells above the insert were removed, 
and those below were fixed and stained with crystal violet. 
Excess dye was washed away with water, and the retained dye was 
extracted. The absorbance at 595 nm was measured. All the bio-
logical assays were performed at 48 hours postinfection, where 
Ran knockdown had already been demonstrated, whereas Ran 
knockdown-induced cell death was not observed (Supplementary 
Figure 2, available online).
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Luciferase Reporter Assay
Luciferase reporter assay was performed using the dual luciferase 
assay kit according to the manufacturer’s instructions (Promega), as 
previously described [18]. Cells were seeded in a 12-well plate and 
cotransfected with the expression vectors and luciferase reporter 
plasmids after 24 hours. Protein was extracted after 36 hours, and 
the firefly luciferase activity was normalized to the internal control 
renilla luciferase activity.
Patients and Specimens
Patients and specimens were described previously (8). A total of 
320 formalin-fixed, paraffin-embedded breast carcinoma speci-
mens were taken from an archive that was collected between 1976 
and 1986 at the Breast Unit, Royal Liverpool Hospital. The mean 
age of the patients was 57 years (range = 29–92 years). No sign 
of metastasis was seen in these patients before specimen procure-
ment. Treatment was either mastectomy or radical mastectomy 
with no prior endocrine or other systemic therapy. Follow-up 
data were collected between 14 and 20 years after treatment had 
been administered. All patient data were made confidential by 
using an anonymized system by the Merseyside Cancer Registry. 
A  total of 113 formalin-fixed, paraffin-embedded early-stage, 
non–small cell lung cancer specimens obtained from Dublin St. 
James’ Hospital and resected by either lobectomy or pneumonec-
tomy were incorporated into a tissue microarray for immunohis-
tochemical staining. Among these patients, 109 had not received 
any form of adjuvant chemotherapy before the procurement of the 
specimens. Anonymized follow-up information, including patient 
survival, histology, and tumor node metastasis classification of 
malignant tumors staging were provided by the Northern Ireland 
Cancer Registry. Informed consent was obtained from patients. 
The Liverpool breast cancer patient cohort was approved by the 
Liverpool Adult Research Ethics Committee (07/H1005/93), 
whereas the Dublin lung cancer patient cohort was approved by 
Saint James’s Hospital and Adelaide and Meath Hospital, Dublin 
(TCD041018/8804).
Immunohistochemistry
Immunohistochemical staining was performed as previously 
described (8) according to the manufacturer’s instructions (DAKO 
Envision+ kit; DAKO, Ely, UK). Ran antibody was used at a dilu-
tion of 1:100, whereas Myc antibody was used at a dilution of 1:250.
Evaluation of Immunohistochemical Staining Results
Evaluation was performed as previously described (8). For breast 
cancer specimens (from Liverpool), the whole section was used 
for staining, and the percentage of stained carcinoma (both nuclei 
and cytoplasm) cells was recorded from at least 10 fields of dupli-
cate histological sections at 200× magnification by two independ-
ent observers and the average result obtained. For analysis, the 
tumors were divided into two groups, classified as immunohis-
tochemically negative if less than 1% of carcinoma cells were 
stained and immunohistochemically positive if greater than 1% 
of carcinoma cells were stained. For lung cancer specimens (from 
Dublin), which were incorporated into the tissue microarray, the 
expression of nuclear and cytoplasmic Ran and nuclear Myc was 
scored from 0 to 5 based on the extent and intensity of the staining 
by two independent observers (H.-F. Yuen and K. O’Byrne.). The 
score was agreed by the two observers. All three cores of each 
specimen in the tissue microarray were scored, and the mean 
score for each specimen was obtained. The mean score was agreed 
upon again by the two observers. The mean score was further 
classified into high- and low-level expression with a cutoff point 
at 2.5. For overall Ran expression, tumors with high levels of both 
nuclear and cytoplasmic Ran staining were considered as high, 
tumors with high level of nuclear and low level of cytoplasmic 
Ran, or vice versa, were considered as intermediate, and tumors 
with low levels of both nuclear and cytoplasmic Ran were consid-
ered as low.
Statistical Analysis
Statistical analysis was performed using SPSS 19.0 software (IBM, 
Armonk, NY). Differences between groups in in vitro experi-
ments were tested by Student t test (two groups) and analysis of 
variance (ANOVA) test with post hoc Games–Howell (comparing 
two groups when more than three groups were tested in the same 
experiment). Differences in expression levels between groups/
samples in the human specimens were analyzed by χ2, Fisher exact 
test, or Mann–Whitney U tests, where applicable. The association 
between the expression level and patient survival was recorded by 
Kaplan–Meier plots and compared by Wilcoxon–Gehan tests. A P 
value of less than .05 was considered statistically significant. All sta-
tistical tests were two-sided.
Analysis of Breast and Lung Cancer Microarray Data
Seven breast cancer datasets [GSE1456 (19), GSE2034 (20), 
GSE3143 (21), GSE4922 (22), GSE7390 (23), GSE11121 (24), 
GSE12276 (25)], each consisting of more than 150 patients, were 
included in the analysis. Five lung cancer datasets [GSE3141 (21), 
GSE4573 (26), GSE8894 (27), GSE13213 (28), GSE14814 (29)], 
each consisting of more than 90 patients, were included in the anal-
ysis. The datasets were preprocessed as previously described using 
R and Bioconductor for normalization (8). The combined breast 
cancer dataset consisted of 1454 patients, whereas the combined 
lung cancer dataset consisted of 586 patients. The patients were 
stratified equally into four groups based on the expression levels of 
Ran and Myc (each group contains 25% of the patients) for further 
statistical analysis. The methodology for the bioinformatics steps is 
provided as Sweave documentation in the Supplementary Methods 
(available online).
results
Effect of Myc on Ran Transcription
Ran has been shown to be upregulated by Myc in a rat cDNA 
microarray study on identification of Myc downstream targets (16), 
whereas our in silico analysis of the Ran upstream sequence revealed 
two Myc binding E-box elements (Supplementary Figure 1, avail-
able online). These results led us to investigate whether Myc is a 
transcriptional activator of Ran. As shown in Figure 1A, overex-
pression of Myc by 2.1-fold resulted in upregulation of endogenous 
Ran protein in the breast MCF10AT cell line by 2.3-fold as deter-
mined by Western blot analysis. The increase in the active form 
of Ran (RanGTP) was also detected upon Myc overexpression 
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Figure  1. Transcriptional regulation of Ras-related nuclear protein 
(Ran) by v-myc myelocytomatosis viral oncogene homolog (Myc). A) 
Left panel, Western blot of Myc-transfected cells. Stable Myc over-
expressing MCF10AT cells had a higher level of Myc (2.1-fold) and a 
higher endogenous protein level of Ran (2.3-fold) compared with the 
vector control MCF10AT cells. Right panel, Immunoprecipitation (IP) 
was performed using anti–Ran binding protein 1 (RanBP1) antibody, 
which binds to Ran (binds only to RanGTP), in both MCF10AT-vector 
and MCF10AT-Myc cells. The resultant pull-down eluents were than 
analyzed by immunoblotting (IB) for Ran. Actin was used as a loading 
control for inputs and negative control for the pull-down assay for the 
two cell lines. B) Gel electrophoresis of the polymerase chain reaction 
(PCR) product from 5’ Rapid Amplification of cDNA Ends (RACE) assay 
showing a specific PCR product of approximately 200 base pairs (bp). 
C) A  schematic diagram of Ran promoter. The cysteine residue at +1 
position is the transcriptional start site of the Ran gene identified by 
sequencing of the PCR product obtained in (B). D) Ran promoter activ-
ity. Transfection of expression vector for Myc and the Ran promoter 
reporter construct in MCF10AT cells resulted in a statistically significant 
increase in the luciferase reporter assay for the Ran promoter activity 
compared with transfection of control vector and Ran promoter reporter 
construct (mean increase = 3.2-fold, 95% confidence interval [CI] = 1.1 
to 5.4; Student t test, P = .01). The histogram is showing mean and 95% 
confidence interval for the promoter activity. E) Chromatin immunopre-
cipitation (ChIP) assay for the Ran promoter region. Myc binds to the 
distal E-box element in human Ran promoter in vivo. Positive control 
template was input genomic DNA, and negative control template was 
water. PCR of immunoglobulin G (IgG) pull-down ChIP products was 
used as a control to the Myc pull-down ChIP products for each cell line 
and are shown side-by-side. F) A  schematic diagram for distal E-box 
mutagenesis of Ran promoter. Mutations were introduced into the 
pGL3-RanPro reporter construct. G) Activities of wild-type (WTpro) and 
mutant (Mutpro) Ran promoter. Myc overexpression resulted in a sta-
tistical significant increase in relative luciferase activity driven by the 
Ran promoter in MCF10AT cells (mean increase = 5.9-fold, 95% CI = 4.54 
to 7.31; analysis of variance [ANOVA] post hoc Games–Howell test, 
P = .004). This Myc-mediated increase in Ran promoter activity was sig-
nificantly reduced to 42% of the WT counterpart (95% CI = 33% to 53%; 
ANOVA post hoc Games–Howell test, P =  .03) when the sequence of 
the distal E-box element of the pGL3-Ranpro construct was mutated. 
The histogram is showing mean and 95% confidence interval for the 
promoter activity. All statistical tests were two-sided.
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in MCF10AT cells by the Ran activation assay (Figure 1A, right 
panel; twofold increase). The transcriptional start site of Ran was 
identified by using the 5’RACE assay, yielding a specific DNA band 
of about 200 base pairs as the 5’RACE polymerase chain reaction 
product (PCR) (Figure  1B). By sequencing this PCR product, 
a cytosine residue at 68 base pairs upstream of the translational 
initiation site was identified as the transcriptional start site of the 
Ran gene in MCF10AT cells (Figure 1C; Supplementary Figure 3, 
available online). Based on the in silico analysis of the upstream 
sequence from the Ran gene and the 5’RACE assay, we cloned the 
putative promoter of Ran, Ranpro, into the luciferase reporter 
construct, pGL3, to produce pGL3-Ranpro by PCR amplification 
using MCF10AT genomic DNA. Using the dual luciferase assay, 
Ran promoter activity was increased by 3.2-fold (95% confidence 
interval [CI] = 1.1 to 5.4; P = .01, Student t test) (Figure 1D) when 
Myc was overexpressed in MCF10AT cells.
In MCF10AT, T47D, and MCF-7 breast cancer cell lines, the 
Ran promoter region containing the distal E-box was enriched in 
Myc chromatin immunoprecipitation (ChIP) products (Figure 1E). 
ChIP assay using Myc antibody resulted in 27% to 33% pull-down 
efficiency of the Ran promoter region containing the distal E-box 
element in all three breast cancer cell lines tested (Figure 1E). In con-
trast, the Ran promoter region containing the proximal E-box ele-
ment was not enriched in the same Myc ChIP products (Figure 1E). 
Our results suggest that Myc binds to this distal E-box element, 
but not to the proximal E-box element, in vivo in these three cell 
lines. The activity of the Ran promoter was statistically significantly 
increased when Myc was overexpressed (mean  =  5.9-fold, 95% 
CI = 4.54 to 7.31; P = .004, ANOVA post hoc Games–Howell test), 
and this increase was statistically significantly reduced to 42% of its 
wild-type counterpart (95% CI = 33% to 53%; P =  .03, ANOVA 
post hoc Games–Howell test) when the distal E-box element was 
mutated compared with the wild-type Ran promoter (Figure 1, F 
and G). Together, our results suggest that Myc binds to the distal 
E-box element in the Ran promoter region to activate expression 
of Ran, which results in an increase in activity of Ran (RanGTP).
Cell Biological Properties Associated With Modulation of 
Myc and Ran Expression
When Myc was overexpressed in an immortalized but otherwise 
normal breast epithelial cell line, MCF10A, endogenous Ran 
expression was increased (Figure  2A). Overexpression of Myc 
resulted in a statistically significant increase in growth of MCF10A 
cells in soft agar (2.5-fold increase, 95% CI = 1.8 to 3.2; P = .008, 
Student t test) (Figure  2B). In addition, knockdown of Myc in 
an invasive breast cancer cell line MDA MB 231 cells resulted in 
downregulation of Ran (Figure 2C) and a concomitant statistically 
significant decrease in the number of colonies formed in soft agar 
to 40% of control (95% CI = 33% to 48%; P = .007, Student t test) 
(Figure  2D), in cell invasion through Matrigel-coated transwell 
(mean = 65% of the control cells, 95% CI = 62% to 68%; P = .008, 
Student t test) (Figure  2E), and in cell adhesion to fibronectin-
coated plate (mean = 58% of control cells, 95% CI = 47% to 70%; 
P =  .04, Student t test) (Figure 2F), which are cellular properties 
associated with the metastatic state in vitro.
Overexpression of Ran also resulted in a statistically significant 
increased number of colonies formed by MCF10A cells in soft agar 
(mean = 7.1-fold, 95% CI = 3.7 to 10.5; P = .01) (Figure 3, A and B). 
We have shown previously that silencing of Ran results in apprecia-
ble apoptosis, which greatly interferes with the interpretation of data 
for investigation of cellular properties associated with metastasis in 
vitro (8). To avoid induction of severe apoptosis while maintaining 
a significant level of Ran knockdown, the viral titer was reduced 
and a less potent small hairpin (sh) RNA targeting Ran, shRan5 was 
used. This protocol resulted in a significant downregulation of Ran 
in MDA MB 231 breast cancer cells without appreciably inducing 
apoptosis, even after 96 hours of viral infection (Supplementary 
Figure 2, available online). Knockdown of Ran in invasive MDA 
MB 231 cells led to a statistically significant decrease in colony 
formation of cancer cells in soft agar to 19% of the control cells 
(95% CI = 17% to 21%; P < .001, Student t test) (Figure 3, C and 
D), in cell invasion through Matrigel-coated transwell membranes 
(38% of the control cells, 95% CI = 15% to 64%; P = .03, Student t 
test) (Figure 3E) and in cell adhesion to fibronectin-coated 96-well 
plates (at 30 minutes, 70% of the control cells, 95% CI = 62% to 
78%; at 60 minutes, 69%, 95% CI = 61% to 77%; Student t-test, 
P = .03) (Figure 3F). These results suggest that Myc and Ran can 
separately stimulate similar cellular properties that are associated 
with cancer progression and metastasis. Overexpression of Ran in 
MCF10AT or knockdown of Ran in MDA MB231 cells did not 
change the expression of Myc (Supplementary Figure 4, available 
online), suggesting that the regulatory link between Myc and Ran 
is unidirectional.
Effect of Ran in Myc-Mediated Cancer Cell Tumorigenesis
Overexpression of Myc resulted in upregulation of endogenous Ran 
in MCF10A immortalized breast epithelial cells and this effect was 
reversed, as shown by Western blot analysis, when the cells were 
infected with the above shRNA targeting Ran, shRan5 (Figure 4A). 
Moreover, when Myc was overexpressed in MCF10A cells, their 
ability to form colonies in soft agar was statistically significantly 
reversed by knocking down expression of Ran (Myc overexpres-
sion: mean = 3.6-fold, 95% CI = 3.0 to 4.3, P =  .002; Myc over-
expression with Ran knockdown: mean = 0.75, 95% CI = 0.41 to 
1.09, P = .13; ANOVA post hoc Games–Howell test) (Figure 4B). 
We then further investigated the importance of Ran in two more 
breast cancer cell lines, MCF-7 and T47D, in which their tum-
origenicity has been shown to be positively associated with Myc 
expression levels (30–33). Knockdown of Ran in these two breast 
cancer cell lines (Figure 4, C and E) resulted in a statistically sig-
nificant decrease in their ability to form colonies in the soft agar 
assay (MCF-7: mean = 9% of control cells, 95% CI = 6% to 12%, 
P = 0.003; T47D: mean = 11% of control cells, 95% CI = 5% to 
18%, P = 0.006, Student t test) (Figure 4, D and F). Together, these 
results suggest that Ran expression is important for these breast 
cancer cell lines to maintain their tumorigenicity in vitro.
Association Between Myc and Ran Expression in Human 
Breast Cancers
Immunohistochemical staining for nuclear Myc protein was 
highly statistically significantly associated with staining for nuclear 
Ran (Fisher exact test, P <  .001), with staining for cytoplasmic 
Ran (P  <  .001), and with overall staining for Ran (P <  .001) 
(Figure 5, A–H).
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Moreover, when the mRNA levels of Ran and Myc from 
seven independent breast cancer datasets were analyzed, statisti-
cally significant positive correlations between the mRNA levels 
of these two genes were observed in all seven individual datasets 
(Spearman rank test, P <  .05) (Figure 5, I–O). When the mRNA 
levels were stratified into four groups evenly and the seven data-
sets were combined (n  =  1454), the positive association between 
Ran and Myc mRNA levels was highly statistically significant (χ2 
test, P < .001) (Figure 5P). These results strongly demonstrate the 
positive association between nuclear Myc and Ran expression in 
patient specimens.
Association of Ran Expression and Patient Survival in 
Myc-Overexpressing Breast Cancers
A statistically significant association between positive nuclear stain-
ing for Myc and a shorter survival time of the patients was observed 
(Wilcoxon–Gehan test, P < .001) (Figure 6A). The median survival 
times for patients with positive and negative staining tumors for 
Figure 2.  Effect of v-myc myelocytomatosis viral oncogene homolog 
(Myc) on in vitro biological properties associated with cancer progres-
sion. A) Western blots for MCF10A-vector control and MCF10A-Myc 
cells. MCF10A-vector control and MCF10A-Myc cells were generated 
by transfection of pBabe-zeo and pBabe-zeo-Myc, respectively, fol-
lowed by selection in zeocin. Stable overexpression of Myc in MCF10A 
cells resulted in upregulation of both Myc (1.7-fold) and the endog-
enous Ras-related nuclear protein (Ran) (2.1-fold). B) Soft agar assay 
for MCF10A-vector and MCF10A-Myc cells. Histogram showing mean 
and 95% confidence interval (CI) for the number of colonies formed in 
soft agar from three independent experiments. The number of colonies 
was statistically significantly greater for MCF10A-Myc cells than for 
MCF10A-vector control cells (2.5-fold, 95% CI = 1.8 to 3.2; Student t test, 
P =  .008). C) Western blots for MDA MB 231-shScr and MDA MB 231-
shMyc cells. MDA MB 231-shScr and MDA MB 231-shMyc cells were 
generated by retroviral infection of pRetrosuper-shScramble RNA and 
pRetrosuper-shMyc RNA, respectively, followed by selection in puromy-
cin. Knockdown of Myc by retroviral infection of Myc shRNA resulted in 
downregulation of both the endogenous Myc (61% reduction) and the 
endogenous Ran (30% reduction) protein levels. D–F) Assays for in vitro 
biological properties associated with cancer progression and metasta-
sis of MDA MB 231-shScr and MDA MB 231-shMyc cells. D) Histogram 
showing mean and 95% confidence interval for the number of colo-
nies formed in soft agar from three independent experiments. MDA 
MB 231-shMyc cells had a statistically significantly decreased number 
of colonies formed in soft agar assay relative to MDA MB 231-shScr 
cells (40% of control, 95% CI = 33% to 48%; Student t test, P =  .007). 
E) The same number of MDA MB 231 cells was seeded in the upper 
chamber of an invasion chamber. They were allowed to migrate through 
the Matrigel-coated membrane overnight using fetal bovine serum as 
chemoattractant. MDA MB 231-shMyc cells had a statistically significant 
decrease in ability to invade through Matrigel compared with MDA MB 
231-shScr cells (65% of the control cells, 95% CI = 62% to 68%; Student 
t test, P = .008). F) Cells adhering to the fibronectin-coated wells were 
fixed with 70% ethanol, washed, and then stained with crystal violet. 
The retained crystal violet was extracted and the absorbance was meas-
ured. MDA MB 231-shMyc cells had a statistically significant decrease in 
ability to adhere to fibronectin compared with MDA MB 231-shScr cells 
(58% of control cells, 95% CI = 47% to 70%; Student t test, P = .04). All 
statistical tests were two-sided.
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nuclear Myc were 70.13 and more than 228 months, respectively. In 
contrast, cytoplasmic staining for Myc was not statistically signifi-
cantly associated with patient survival time (Wilcoxon–Gehan test, 
P = .34) (Figure 6B). Using Cox univariable regression analysis, posi-
tive staining for nuclear Myc was statistically significantly associated 
with an increased risk of patient death of 10.6-fold (95% CI = 5.2 to 
21.8; P < .001). These results suggest that an increased expression of 
Myc may promote metastatic progression of breast cancer, possibly 
through its nuclear rather than its cytoplasmic activity.
In our cohort of breast cancer patients with positive staining for 
nuclear Myc, the association between positive staining for nuclear 
Ran and survival was highly statistically significant (χ2 = 24.1; rela-
tive risk [RR] = 9.10, 95% CI = 3.3 to 24.7; P < .001) (Figure 6C). 
In this group of patients, the median survival time for those with 
positive staining for nuclear Ran was 56 months, whereas it was 
216 months for those with negative staining. In contrast, much less 
difference in median survival time between positive and negative 
nuclear Ran staining was observed in those patients with negative 
staining for nuclear Myc. The median survival time for those with 
positive staining for nuclear Ran was 204 months, and it was more 
than 228  months for those with negative staining (Figure  6D). 
Likewise, in patients with positive staining for nuclear Myc, the 
association between positive staining for cytoplasmic Ran and 
survival was statistically significant (χ2 = 9.664; RR = 2.08, 95% 
CI = 1.41 to 3.08; P = .002) (Figure 6D). In this group of patients, 
the median survival time for those with positive staining for cyto-
plasmic Ran was 56 months, whereas it was 190 months for those 
with negative staining. In contrast, much less difference in median 
Figure 3. Effect of Ras-related nuclear protein (Ran) on in vitro biologi-
cal properties associated with cancer progression and metastasis. A) 
Western blots for MCF10A-vector and MCF10A-Ran cells. MCF10A-vector 
control and MCF10A-Ran cells were generated by retroviral infection of 
pBabe-hygro and pBabe-hygro-Ran, respectively, followed by selection 
in hygromycin. A higher protein level of Ran (2.1-fold) was detected in 
MCF10A-Ran cells compared with MCF10A-vector control cells. B) Soft 
agar assay for MCF10A-vector and MCF10A-Ran cells. Histogram show-
ing mean and 95% confidence interval (CI) for the number of colonies 
formed in soft agar from three independent experiments. MCF10A-Ran 
cells had a statistically significant 7.1-fold (95% CI  =  3.7 to 10.5-fold; 
Student t test, P = .01) increase in ability to form colonies in soft agar 
assay compared with MCF10A-vector control cells. C) Western blots for 
MDA MB 231–short hairpin Scramble (shScr) and MDA MB 231–short 
hairpin RNA against Ran (shRan) cells. MDA MB 231-shScr and MDA 
MB 231-shRan cells were generated by lentiviral infection of pLKO.1-
shScramble RNA and pLKO.1-shRan RNA, respectively, followed by 
selection in puromycin. MDA MB 231-shRan cells had a lower level of 
Ran protein at various times after infection (90%, 87%, and 83% reduc-
tion at 48, 72, and 96 hours, respectively). D–F) Assays for biological 
properties associated with cancer progression and metastasis of MDA 
MB 231-shScr and MDA MB 231-shRan cells. D) Histogram showing 
mean and 95% confidence interval for the number of colonies formed in 
soft agar from three independent experiments. MDA MB 231-shRan cells 
formed statistically significantly fewer colonies in soft-agar compared 
with MDA MB 231-shScr cells (19% of the control cells, 95% CI = 17% to 
21%; Student t test, P < .001). E) MDA MB 231-shRan cells had a statisti-
cally significant reduced ability of invading through Matrigel compared 
with MDA MB 231-shScr cells (38% of the control cells, 95% CI = 13% to 
64%; Student t test, P = .03). F) MDA MB 231-shRan cells had a statisti-
cally significantly decreased ability to adhere to fibronectin compared 
with MDA MB 231-shScr cells (at 30 minutes: 70% of the control cells, 
95% CI = 62% to 78%; at 60 min: 69%, 95% CI = 61% to 77%; Student t 
test, P = .03). All statistical tests were two-sided.
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survival time between positive and negative cytoplasmic staining 
for Ran was observed in those patients with negative staining for 
nuclear Myc. The median survival time for those with positive 
staining for cytoplasmic Ran was 204  months, and it was more 
than 228 months for those with negative staining (Figure 6D). In 
the combined breast cancer datasets, a high level of Ran mRNA 
was also statistically significantly associated with a shorter survival 
time (7 independent datasets, n  =  1454; χ2  =  14.26; RR  =  1.35, 
95% CI = 1.16 to 1.58; P < .001) (Supplementary Figure 5A, avail-
able online). Moreover, a high level of Ran mRNA was statisti-
cally significantly associated with a higher relative risk (n = 728; 
χ2 = 8.30; RR = 1.41, 95% CI = 1.12 to 1.78; P = .004) (Figure 6G) 
in patients expressing a high level of Myc mRNA and was less 
potent in those patients expressing a low level of Myc mRNA 
(n = 726; χ2 = 4.39; RR = 1.28, 95% CI = 1.02 to 1.61; P =  .04) 
(Figure 6H).
Figure 4. Effect of Ras-related nuclear protein (Ran) on v-myc myelocytoma-
tosis viral oncogene homolog (Myc)–driven in vitro biological properties 
associated with cancer progression. A) Western blots for MCF10A-vector 
control–short hairpin Scramble (shScr), MCF10A-Myc-shScr and MCF10A-
Myc– short hairpin RNA against Ran (shRan) cells. MCF10A-vector control-
shScr, MCF10A-Myc-shScr, and MCF10A-Myc-shRan cells were generated 
by lentiviral infection of pLKO.1-shScr, pLKO.1-shScr, and pLKO.1-shRan, 
respectively, followed by selection in puromycin. MCF10A-Myc-shScr cells 
had a higher level of endogenous Ran protein (1.6-fold) compared with 
MCF10A-vector control-shScr cells. This increase in Ran protein level was 
abolished in MCF10A-Myc-shRan cells upon infection of pLKO.1-shRan 
construct (87% reduction). B) Histogram showing mean and 95% confi-
dence interval (CI) from three independent experiments for the results 
from the soft agar assay for MCF10A-vector control-shScr, MCF10A-Myc-
shScr, and MCF10A-Myc-shRan cells. MCF10A-Myc-shScr cells had a 
statistically significant 3.6-fold (95% CI = 3.0 to 4.3; analysis of variance 
[ANOVA] post hoc Games–Howell test, P = .002) increased ability to form 
colonies in soft agar assay. This increase in soft agar colony formation was 
reduced in MCF10A-Myc-shRan cells, which resulted in no statistically 
significant difference to MFC10A-vector control-shScr cells (mean = 75% 
of control, 95% CI = 41% to 109%; ANOVA post hoc Games–Howell test, 
P = .13). C) Western blots for MCF-7-shScr and MCF-7-shRan cells. MCF-
7-shScr and MCF-7-shRan cells were generated by lentiviral infection 
of pLKO.1-shScr and pLKO.1-shRan, respectively, followed by selection 
in puromycin. Myc, Ran, and Actin expression levels for these two cell 
lines were assessed by Western blot. D) Histogram showing mean and 
95% confidence interval from three independent experiments for the 
results from the soft agar assay for MCF-7-shScr and MCF-7-shRan cells 
(mean = 9% of control cells, 95% CI = 6% to 12%; Student t test, P = .003). 
E) Western blots for T47D-shScr and T47D-shRan cells. T47D-shScr and 
T47D-shRan cells were generated by lentiviral infection of pLKO.1-shScr 
and pLKO.1-shRan, respectively, followed by selection in puromycin. Myc, 
Ran, and Actin expression levels for these two cell lines were assessed by 
Western blot. F) Histogram showing mean and 95% confidence interval 
from three independent experiments for the results from the soft agar 
assay for T47D-shScr and T47D-shRan cells (mean = 11% of control cells, 
95% CI = 5% to 18%; Student t test, P =  .006). All statistical tests were 
two-sided.
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Figure 5. Association of protein and mRNA levels of v-myc myelocy-
tomatosis viral oncogene homolog (Myc) and Ras-related nuclear 
protein (Ran) in breast cancer specimens. A–F) Representative images 
of immunohistochemical staining of breast cancers for Myc (A, C, 
E) and Ran (B, D, F). Two separate histological sections from each of 
three tumors are shown: tumor 1 (A, B), tumor 2 (C, D), tumor 3 (E, F). 
Sections were immunohistochemically stained for Myc (A, C, E) and 
for Ran (B, D, F). In tumor 1, carcinoma cells (c) were unstained for 
Myc (A) and for Ran (B), whereas reactive stromal cells (arrows) were 
well stained with either antibody. In tumor 2, nuclei of carcinoma cells 
were well stained for Myc (C) (arrows) and for Ran (D) (arrows); there 
was little or no staining of carcinoma cell cytoplasm with either anti-
body. In tumor 3, the cytoplasm and some nuclei (E) (arrows) of the 
carcinoma cells were stained for Myc, whereas only the cytoplasm (F) 
was stained for Ran. Magnification 390× (A–D), 960× (E, F). Scale bars, 
25 µm (A–D); 10 µm (E, F). G and H) Comparison of immunohistochemi-
cal staining in all the 288 different tumors for staining for nuclear Myc 
and for nuclear Ran (G) and staining for nuclear Myc and for cytoplas-
mic Ran (H). Fisher exact test was used. I–P) Comparison of relative 
levels of Myc and Ran mRNA in breast cancer datasets available in the 
Gene Expression Omnibus (GEO) database. Relative mRNA levels of 
Myc and Ran was extracted from the GEO database and normalized 
by using R and Bioconductor as previous described (8). Datasets with 
patient number greater than or equal to 150 were included, and the cor-
relations between relative mRNA levels of Myc and Ran in each data-
set were compared by nonparametric bivariable correlation analysis 
(Spearman rank test) using SPSS. I–O) In all the datasets tested in this 
study—GSE1456 (n = 159) (I), GSE2034 (n = 286) (J), GSE3143 (n = 158) 
(K), GSE4922 (n = 255) (L), GSE7390 (n = 198) (M), GSE1121 (n = 200) 
(N), and GSE12276 (n  =  204) (O)—the relative mRNA levels of Myc 
and Ran were significantly positively correlated (Spearman rank test; 
P < .05). P) Histogram showing percentage of cases with different levels 
of Ran mRNA in patients with different levels of Myc mRNA. The seven 
datasets were combined into one by stratifying the mRNA levels of 
Myc and Ran into four groups equally using the three quartiles as cut-
off points. In the combined breast cancer dataset (n = 1454), the asso-
ciation between mRNA levels of Myc and Ran was tested by Spearman 
rank test. Statistically significantly more patients with a higher level of 
Myc mRNA also had a higher level of Ran mRNA (χ2 test; P < .001). All 
statistical tests were two-sided.
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Correlation Between Myc and Ran Expression in Human 
Lung Cancers
In A549 lung cancer cells, overexpression of Myc also transacti-
vates the Ran promoter activity in vitro by luciferase reporter assay 
(Supplementary Figure  6A, available online). Myc expression in 
A549 cells was shown to be associated with an increase prolifera-
tion and tumorigenesis (34). We also found that knockdown of Ran 
in this cell line resulted in a statistically significant reduction in the 
ability of the cells to form colonies in soft agar (9% of the control 
cells, 95% CI = 6% to 12%; P = .002) (Supplementary Figure 6, B 
Figure 6. Association of expression of v-myc myelocytomatosis viral 
oncogene homolog (Myc) and Ras-related nuclear protein (Ran) alone 
and in combination with patient survival in breast cancer. A–F) Kaplan–
Meier plots of the cumulative proportion of patients surviving with 
time in months of the Liverpool breast cancer patient cohort (n = 288) 
are shown for tumors with nuclear Myc alone (A), tumors stained for 
cytoplasmic Myc alone (B), nuclear Myc-positive tumors with either 
positive or negative staining for nuclear Ran (C), nuclear Myc-negative 
tumors with either positive or negative staining for nuclear Ran (D), 
nuclear Myc-positive tumors stained for either positive or negative 
staining for cytoplasmic Ran (E), and nuclear Myc-negative tumors 
stained for either positive or negative staining for cytoplasmic Ran (F). 
G, H) Kaplan–Meier plots of cumulative proportion of patients surviv-
ing with time in years of the combined breast cancer dataset (n = 1454) 
from the Gene Expression Omnibus database for mRNA level of Ran 
in patients with a high level (G) and a low level (H) of Myc mRNA 
expression. Wilcoxon–Gehan test was used. All statistical tests were 
two-sided.
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and C, available online). The protein and mRNA expression lev-
els of Ran and Myc were also analyzed in our lung cancer patient 
cohort and five independent lung cancer datasets available in the 
Gene Expression Omnibus database. As shown in Figure 7, increased 
staining of nuclear Myc protein was statistically significantly associ-
ated with nuclear (Spearman rank test, P =  .002) (Figure 7, A and 
B), cytoplasmic (P = .01) (Figure 7, A and C), and overall (P = .001) 
(Figure 7, A and D) staining for Ran protein. Similarly, the level of 
Ran mRNA was statistically significantly correlated with that of Myc 
mRNA in all five independent lung cancer datasets analyzed (P < .05) 
(Figure 7, E–I). Importantly, when the mRNA levels were stratified 
into four equal groups and the five datasets were combined, a statis-
tical significant association between Myc and Ran mRNA levels in 
lung cancer specimens was also observed (P < .001) (Figure 7J).
Association of Ran Expression and Patient Survival in 
Myc-Overexpressing Lung Cancers
Similar to the breast cancer patients, in lung cancer patients with a 
high immunohistochemical staining for nuclear Myc, a high level 
of staining for Ran protein was statistically significantly associated 
with a shorter survival time (Wilcoxon–Gehan test, P = .048; uni-
variable Cox regression, χ2 = 6.04, RR = 2.8, 95% CI = 1.2 to 6.3, 
P = .01) (Figure 8A). In contrast, no statistical significant association 
between Ran expression and survival was observed in patients with 
a low-level staining for nuclear Myc (Wilcoxon–Gehan test, P = .20) 
(Figure 8B). When analyzing the combined lung cancer datasets, a 
high level of Ran expression was statistically significantly associated 
with poorer survival (Wilcoxon–Gehan test, P =  .001; univariable 
Cox regression, χ2 = 11.0, RR = 1.55, 95% CI = 1.12 to 2.00, P = .01) 
(Supplementary Figure 5B, available online). Moreover, in patients 
expressing a high level of Myc mRNA, a high level of Ran expression 
was also statistically significantly associated with a shorter survival 
time (Wilcoxon–Gehan test, P = 0.001; univariable Cox regression, 
χ2 = 8.17, RR = 1.99, 95% CI = 1.24 to 3.19, P = .01) (Figure 8C). 
Again, Ran mRNA expression was not statistically significantly asso-
ciated with survival in patients with a low level expression of Myc 
(Wilcoxon–Gehan test, P = .12) (Figure 8D). Together, these results 
suggest that Ran expression may be an important determinant of 
Myc-mediated lung cancer progression.
Discussion
Previously, we have shown that Ran silencing results in more 
potent apoptotic response in cancer cells with activated PI3K/
Figure  7.  Association of expression of v-myc myelocytomatosis viral 
oncogene homolog (Myc) and Ras-related nuclear protein (Ran) in 
lung cancer patients. A) Representative images of immunohistochemi-
cal staining for Myc and Ran in lung cancer specimens. Top panel: scale 
bar = 100µm; bottom panel: scale bar = 40 µm. B–D) Quantitative com-
parison of staining for Myc and Ran in different tumors for staining for 
nuclear c-Myc and for nuclear Ran (B), staining for nuclear c-Myc and for 
cytoplasmic Ran (C), and staining for nuclear c-Myc and overall Ran (D). 
Fisher exact test (B, C) and χ2 test (D) were used. E–J) Comparison of rela-
tive levels of Myc and Ran mRNA in lung cancer datasets available from 
the Gene Expression Omnibus (GEO) database. E–I) Relative mRNA lev-
els of Myc and Ran was extracted from the GEO database and normalized 
by using R and Bioconductor as previously described (8). Datasets with 
patient number greater than or equal to 90 were included, and the correla-
tions between relative mRNA levels of Myc and Ran in each dataset were 
compared by nonparametric bivariable correlation analysis (Spearman 
rank test) using SPSS. In all the datasets tested in this study—GSE3141 
(n = 111) (E), GSE4573 (n = 130) (F), GSE8894 (n = 138) (G), GSE13213 
(n = 117) (H), and GSE14814 (n = 90) (I)—the relative mRNA levels of Myc 
and Ran were significantly positively correlated (Spearman rank test; 
P < .05). Note that the values for Myc and Ran in the GSE13213 dataset 
were negative because the microarray was performed using a two-chan-
nel method where the reference sample was RNA extracted from 20 lung 
cancer cell lines; the results indicated that most of the human specimens 
had a lower expression of Myc and Ran compared with the reference 
sample (20 lung cancer cell lines). J) The five datasets were combined 
into one by stratifying the mRNA levels of Myc and Ran into four groups 
equally using the three quartiles as cut-off points. In the combined lung 
cancer dataset (n = 586), the association between mRNA levels of Myc 
and Ran was tested by Spearman rank test. Statistically significantly 
more patients with a higher level of Myc mRNA also had a higher level of 
Ran mRNA (χ2 test; P < .001). All statistical tests were two-sided.
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Akt/mTORC1 and Ras/MEK/ERK pathways. In this study, we 
investigated the role in Ran in myc-induced tumorigenesis in 
both breast and lung cancers, independent of instant apoptotic 
response, by using a less potent shRNA for Ran knockdown. In 
this study, we have demonstrated in immortalized breast epithe-
lial MCF10A cells and breast cancer MDA MB 231 cells that 
both Ran and Myc in vitro are important in enhancing cellular 
properties, including colony growth in soft agar, cell adhesion, 
and cell invasion, associated with cancer aggressiveness. When 
the upstream region of Ran is examined, Myc binds to the dis-
tal, but not the proximal, E-box element and can transactivate 
the Ran promoter to upregulate Ran expression. The Myc–Ran 
promoter interaction has also been demonstrated in two other 
reports using a ChIP sequencing technique (35,36). We have 
further demonstrated that the in vitro observations are of clini-
cal relevance by showing that Myc and Ran protein levels are 
significantly positively correlated in 288 breast and 102 lung 
cancer patients and that their mRNA levels are also significantly 
positively correlated in 1454 breast and 586 lung cancer patients. 
In vitro, Ran knockdown suppresses the Myc-enhanced colony 
formation in soft agar in an immortalized breast epithelial cell 
line. Most important, we have shown that in both breast and lung 
cancer patients with a high level of Myc expression within the 
primary tumors, Ran overexpression is associated with increased 
death rates. These results provide clinical support to our findings 
in cultured cells that Ran may be an important downstream effec-
tor of Myc-mediated cancer progression.
In this study, we have also found that Ran is a direct transcrip-
tional target of Myc and that a high level of Ran expression is 
important for the function of Myc overexpression in breast can-
cer cells in vitro and in Myc-overexpressing cancer patients. Myc 
is overexpressed in more than 40% of human cancers (37) and is, 
Figure  8. Association of expression of v-myc myelocytomatosis viral 
oncogene homolog (Myc) and Ras-related nuclear protein (Ran) alone 
and in combination in lung cancer patients. A and B) Kaplan–Meier plots 
of the cumulative proportion of patients surviving with time in months 
of the Dublin lung cancer patient cohort are shown for tumors stained 
for low (A) and high (B) levels of nuclear Myc for high, intermediate, 
and low levels of overall (cytoplasmic and nuclear) Ran protein expres-
sion. C and D) Kaplan–Meier plots of the cumulative proportion of 
patients surviving with time in months of the combined lung cancer 
dataset (n = 586) from Gene Expression Omnibus database for mRNA 
level of Ran in patients with low (C) and high (D) levels of Myc mRNA. 
Wilcoxon–Gehan test was used. All statistical tests were two-sided.
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therefore, a good target for cancer therapy. Our results suggest a 
novel approach for targeting Myc-overexpressing tumors in that 
silencing of Ran expression may inhibit Myc-driven cancer pro-
gression. Identification of small molecules that inhibit Ran-RCC1/
Ran-RanGAP interactions or that downregulate Ran expression is 
underway, and these molecules could be tested in vitro and in vivo 
to validate our hypothesis.
In this study, we have shown that Ran expression is impor-
tant in Myc-overexpressing breast and lung cancers. However, 
this  study also had some limitations. The study was retrospec-
tive,  and, although designed as intent-to-treat, the actual treat-
ments of patients were heterogeneous. Small molecules that inhibit 
Ran expression or functions are yet to be identified. The investiga-
tion of these molecules on inhibiting cancer progression in human 
patients in a prospective setting is therefore highly warranted.
In our previous report (8) on breast and lung cancers, we showed 
that a high level of Ran expression is associated with a shorter sur-
vival time in patients, particularly those with K-Ras–activating 
mutations, with overexpression of c-Met and osteopontin, and with 
a PIK3CA activating gene signature, and in this study, we have 
shown this association in patients with Myc overexpression. These 
results also suggest that a high level of Ran expression is required for 
cancers driven by the common oncogenic mutations to express their 
aggressive behavior. Therefore, Ran may be an important therapeu-
tic target for cancer patients harboring these oncogenic changes. In 
vitro experimental results from us and  from  others, obtained by 
silencing Ran, further support the clinical association. Cancer cells 
are more susceptible to Ran silencing than normal cells (6), whereas 
colon cancer cell lines harboring K-Ras–activating mutation are 
more susceptible to Ran  silencing than the K-Ras wild-type iso-
genic counterparts (7,8). In conclusion, our data together suggest 
that Ran is a major downstream target of Myc-overexpressing can-
cer cells and that Ran may be a novel therapeutic target for cancer 
cells with oncogenic changes, including, but not limited to, Myc 
overexpression.
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